Tg Therapeutics Inc (TGTX) — 13F Holders Deep Dive (Q2 2026)

TGTX ranks #1392 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

TGTX is a top-conviction position for Occam Crest Management LP — at 11.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TGTX belongs to BlackRock, Inc., but the position matters far more to Occam Crest Management LP, who has 11.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its TGTX position for two straight quarters, increasing it by $560.1M to reach $1.2B today.

Invesco Ltd. has trimmed its TGTX position for two straight quarters, cutting it by $25.6M while still holding $22.4M.

TGTX is up 0.7% today, and institutions have been net buyers of $890.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

TGTX posted net income of $441.5M over the trailing twelve months, and currently trades at a P/E of 19.9.

• Profitable — net income of $441.5M over the trailing twelve months
• Revenue grew 76.1% year over year
• Net income improved year over year, from $60.5M to $441.5M
• Operating cash flow was negative, using $24.8M in cash
• Current ratio of 4.10x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.64x equity — within a conventional range